Penn Center

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Friday, February 23, 2024

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

CorVista Health Announces Anjali Tiku Owens, M.D. Appointment to Medical Advisory Board

Retrieved on: 
Tuesday, January 23, 2024

CorVista Health, Inc ., a leading digital health company dedicated to improving cardiovascular disease diagnosis announces expansion of their Medical Advisory Board with the appointment of Dr. Anjali Tiku Owens.

Key Points: 
  • CorVista Health, Inc ., a leading digital health company dedicated to improving cardiovascular disease diagnosis announces expansion of their Medical Advisory Board with the appointment of Dr. Anjali Tiku Owens.
  • We are thrilled to welcome Dr. Anjali Tiku Owens to our esteemed board," said Don Crawford, President and CEO of CorVista Health.
  • Dr. Tiku Owens joins a distinguished group of medical professionals on the CorVista Health Medical Advisory Board, contributing to the company's mission to improve the availability and accessibility of cardiovascular disease diagnosis.
  • I look forward to collaborating with CorVista and the Medical Advisory Board to make a meaningful impact on patient outcomes."

The Global Wellness Summit Honors Diverse Group of Pioneers for Their Achievements in Mental Wellness, Innovation and the Science of Wellness

Retrieved on: 
Thursday, November 16, 2023

MIAMI, Nov. 16, 2023 /PRNewswire-PRWeb/ -- The Global Wellness Summit (GWS), the foremost gathering of international leaders in the $5.6 trillion global wellness economy, wrapped up its annual conference in Miami last week, where the organization presented three prestigious awards to high-profile (and very different) leaders for their impact not only on the wellness industry but the world.

Key Points: 
  • Her transparency about needing to focus on her mental health sparked a global conversation on how it is as important as physical health, for athletes and for all.
  • "We're thrilled to recognize the incredible achievements of Simone Biles at this year's Global Wellness Summit, both as a superhuman athlete and a deeply human champion for mental wellbeing," said Susie Ellis, GWS chair & CEO.
  • The Debra Simon Award for Furthering Mental Wellness was presented to Biles by the CEO of Fountain Life Bill Kapp, MD, on behalf of the GWS Advisory Board.
  • The Bennett Family Award for Collaboration in the Science of Wellness was presented to Roizen on behalf of the GWS Advisory Board by Nicola Finley, MD.

CHOP and Penn Researchers Receive $50 Million NIH Grant to Study Impact of Environmental Factors on Pregnancy and Children's Health

Retrieved on: 
Monday, October 2, 2023

PHILADELPHIA, Oct. 2, 2023 /PRNewswire/ -- A multidisciplinary group of researchers from Children's Hospital of Philadelphia (CHOP) and Penn Medicine have received a $50 million grant from the National Institutes of Health (NIH) to study the impact of environmental influences on pregnancy and children's health. The research program is part of the NIH's Environmental influences on Child Health Outcomes (ECHO) Program, which funds research to uncover how environmental exposures during preconception, pregnancy and early life affect children's long-term health.

Key Points: 
  • PHILADELPHIA, Oct. 2, 2023 /PRNewswire/ -- A multidisciplinary group of researchers from Children's Hospital of Philadelphia (CHOP) and Penn Medicine have received a $50 million grant from the National Institutes of Health (NIH) to study the impact of environmental influences on pregnancy and children's health.
  • The research program is part of the NIH's Environmental influences on Child Health Outcomes (ECHO) Program , which funds research to uncover how environmental exposures during preconception, pregnancy and early life affect children's long-term health.
  • "We know that communities are not equally exposed to environmental toxicants, and we also know that health inequities and disparities are an ongoing public health problem.
  • "The Penn-CHOP ECHO Study Site now joins the Philadelphia Regional Center for Children's Environmental Health , the Penn Center of Excellence in Environmental Toxicology (CEET) , and the CHOP Center for Health Equity in leading the way to improve children's health, support environmental justice, and reduce health disparities."

Global Wellness Institute Welcomes Three New Wellness Experts to Board of Advisors

Retrieved on: 
Tuesday, January 24, 2023

MIAMI, Jan. 24, 2023 /PRNewswire-PRWeb/ -- The nonprofit Global Wellness Institute™ (GWI), the leading research and educational resource for the global wellness industry, today announced Bill Kapp, Fountain Life™ CEO & co-founder, Anjan Chatterjee, MD, FAAN, founding director of the Penn Center for Neuroaesthetics, and Freddie Moross, managing director of UK-based Myndstream, which creates and designs music for health and wellbeing, have joined the prestigious GWI board of advisors. The new appointments to the 21-member board were announced by the Institute's Chair and CEO Susie Ellis.

Key Points: 
  • "These members of GWI's board of advisors are a perfect fit for our mission to empower wellness, in its many forms, worldwide," said Ellis.
  • "Dr. Bill Kapp is passionate about transforming the healthcare system into one that is proactive and grounded in scientific data.
  • Dr. Anjan Chatterjee was the first to bring worldwide attention to the connection between wellness and the perception of beauty.
  • Freddie Moross received the Debra Simon Award for Leader in Furthering Mental Wellness at the 2022 Global Wellness Summit.

Stroud Water Research Center honors Michael E. Mann, Ph.D., leading climate scientist and author

Retrieved on: 
Friday, November 4, 2022

Avondale, PA, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Stroud Water Research Center bestowed the 2022 Stroud Award for Freshwater Excellence to Michael E. Mann, Ph.D., one of the worlds leading voices on climate change on Thursday, November 3.

Key Points: 
  • Avondale, PA, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Stroud Water Research Center bestowed the 2022 Stroud Award for Freshwater Excellence to Michael E. Mann, Ph.D., one of the worlds leading voices on climate change on Thursday, November 3.
  • Executive Director David Arscott, Ph.D., said, Water is the primary medium through which we feel the impacts of climate change, and Michael Mann is a leading voice on climate change.
  • His groundbreaking research and masterful science communication have given weight and shape to the conversations needed to initiate climate action.
  • Stroud Water Research Center advances knowledge and stewardship of freshwater systems through global research, education, and restoration.

Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office

Retrieved on: 
Wednesday, September 21, 2022

HADDONFIELD, N.J., Sept. 21, 2022 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on June 28, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,369,618 ('618 patent) entitled "Compounds, Compositions Methods for Prevention and/or Treatment of Cancer".

Key Points: 
  • "We are extremely pleased that the USPTO has issued this critical patent, the third essential patent in our GPER agonist patent portfolio," commented Patrick Mooney, MD, CEO of Linnaeus.
  • "We believe that the issued claims will provide critical market protection for LNS8801 through at least 2037.
  • As we continue to collect very promising data from our clinical trials of LNS8001, we plan to prosecute the '618 patent on a worldwide basis."
  • Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics that target G protein-coupled receptors.

Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 at 2022 ASCO Annual Meeting

Retrieved on: 
Monday, June 6, 2022

HADDONFIELD, N.J., June 6, 2022 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of clinical data from its phase 1/2 clinical trial of LNS8801 in combination with pembrolizumab in patients who have developed secondary resistance to antiPD-1/L1 therapy at the 2022 ASCO Annual Meeting.

Key Points: 
  • HADDONFIELD, N.J., June 6, 2022 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of clinical data from its phase 1/2 clinical trial of LNS8801 in combination with pembrolizumab in patients who have developed secondary resistance to antiPD-1/L1 therapy at the 2022 ASCO Annual Meeting.
  • These biomarkers are being further validated and will aid in the selection of patients in future clinical studies.
  • "We are very pleased to showcase these data at ASCO," commented Patrick Mooney, MD, CEO of Linnaeus.
  • Additionally, LNS8801 has demonstrated target engagement, c-Myc protein depletion, and clinical benefit in some patients with advanced cancer.

Vital Start Health Launches COURAGE, the First Virtual Reality Enabled, Equitable Telemedicine Platform for Maternal Mental Health and Well-Being

Retrieved on: 
Thursday, April 14, 2022

"Vital Start Health's unique tech-focused approach to maternal mental health and strong market potential puts it in a great position to succeed.

Key Points: 
  • "Vital Start Health's unique tech-focused approach to maternal mental health and strong market potential puts it in a great position to succeed.
  • The platform empowers patients with experiential practice and immersive psychoeducation, with the goal of driving better diagnoses, targeted treatment, leading to greater effectiveness and outcomes.The American Psychological Association has recommended Virtual Reality for Mental Health.
  • The services provide the mothers with a personal trainer for maternal well-being enabled through affordable Virtual Reality options.
  • With these key partnerships, Vital Start aims to grow enterprise sales across health systems, health insurance companies, employers and pharmaceuticals.

Linnaeus Therapeutics Announces Presentation of Pre-Clinical Data of LNS8801 at 2022 AACR Annual Meeting

Retrieved on: 
Tuesday, April 12, 2022

Ambrosini and colleagues have demonstrated that LNS8801 has potent anti-cancer activities in models of uveal melanoma cells.

Key Points: 
  • Ambrosini and colleagues have demonstrated that LNS8801 has potent anti-cancer activities in models of uveal melanoma cells.
  • "We are extremely pleased to showcase these data at AACR," commented Patrick Mooney, MD, CEO of Linnaeus.
  • "These data demonstrate that LNS8801 has activity in preclinical models of uveal melanoma in vitro and in vivo.
  • Importantly, these data are consistent with the clinical data in our on-going studies of LNS8801 in advanced cancer patients.